A water-soluble presentation for broiler and layer operations is prepared by blending the API with anhydrous dextrose, citric acid monohydrate, and fumed silica to achieve a reconstituted drinking-water pH of 3.8–4.2. The powder is sifted through a 60 mesh stainless-steel rotary sifter and transferred to a V-type blender operated at 12 rpm for 15 minutes; final moisture is held at ≤7.0% w/w by loss-on-drying because higher moisture accelerates caking in humid poultry houses. The API weight fraction in the finished soluble powder is fixed at 15% and adjusted by batch assay to compensate for extractable matter variation; bulk density shifts between 0.42 g/mL and 0.55 g/mL require metering screw speed corrections on the filling line. Compliance for this presentation requires the API to meet the Xiaoshi Pingwei Powder monograph in the Chinese Veterinary Pharmacopoeia 2020 edition, including heavy metals, ash, and microbial limits. Residual solvent testing follows VICH GL18, and the finished powder is released only after total aerobic microbial count by ISO 4833-1:2013 and Enterobacteriaceae by ISO 21528-2:2017 meet the oral-powder acceptance criteria of the destination market. The terminal product is a water-soluble powder packed in 100 g or 500 g HDPE jars or 1 kg PET/aluminum/PE pouches for dilution into poultry drinking-water systems.

On production-scale lines, the limiting step is sifter blinding caused by hygroscopic fines adhering to 60 mesh screens when relative humidity exceeds 55%; the operation therefore requires a dehumidified transfer room at ≤40% RH and 316L stainless-steel contact surfaces. Citrate-buffered reconstitution at pH 4.0 can mobilize aluminum from some anti-caking agents above 0.2 mg/L in acidic dosing solutions; therefore fumed silica at 0.5% is selected instead of aluminum-bearing carrier media. Incoming dextrose lots are restricted to total aerobic microbial count ≤10³ CFU/g by ISO 4833-1:2013 before use.

What Addition Ratios Govern Medicated Premix Carryover in Swine Feed Lines?

Premix manufacturing for grower-finisher swine feed uses a stepwise preblend because the API powder has an angle of repose above 40° when unprocessed, which prohibits direct micro-ingredient metering. A 25 wt% active premix is prepared in a 500 L horizontal ribbon mixer by 1:10 staged dilution into ground corn cob or rice husk carrier. After the final addition step, 1.5% soybean oil is spray-applied as a dust-control agent. The finished premix is included at 4–6 kg per 1000 kg complete feed, resulting in an API concentration of 0.10–0.15% in the final feed. Mixing uniformity is verified by tracer salt analysis with a coefficient of variation ≤5%. Compliance for this presentation depends on the regulatory status of the API in the destination market. If the formula is considered a veterinary medicinal product, authorization under Regulation (EU) 2019/6 is required; if a feed additive route is pursued, registration under Regulation (EC) No 1831/2003 is involved. Hygiene limits follow GB 13078-2017 for mycotoxins, heavy metals, and pathogenic bacteria, and sampling follows ISO 6497:2005. The terminal product is a medicated premix in 20 kg PE-lined multiwall bags for use in swine feed mills.

Carryover after premix batches is a known source of feed-line contamination because the extract powder adheres to ribbon mixer troughs, bucket elevator buckets, and drag conveyor flights. A dry flush with 10 kg of ground corn per 100 kg mixer capacity is run between batches when the next feed phase is non-medicated feed; a vacuum line operated for 15 minutes on the mixer lid reduces the first-flush carryover peak from above 0.3% to below 0.1% in the subsequent non-medicated line. Feed mills without a secured clean-out procedure should not alternate this premix with non-medicated rations unless flush quantities and sequencing are defined in the HACCP plan.

Compression Performance Limits for Hygroscopic Digestive Tonic Tablets

The powder is evaluated for tablet production as a dry-granulated component, not a direct-compression material, because moisture uptake above 5.0% w/w reduces flow and increases sticking on rotary press punch faces. Formulation development starts with 18–28 wt% API, 65–75 wt% silicified microcrystalline cellulose, 2–4 wt% crospovidone, and 0.5–1.0 wt% magnesium stearate. Roller compaction at 4–6 kN/cm with a 2.0 mm screen size produces granules with a D50 of 250–400 μm. Compression on a 12-station rotary press at a turret speed of 30–40 rpm yields tablet hardness of 60–80 N and friability below 1.0% by USP 1216. Tablet disintegration is controlled by USP 701, with complete disintegration within 15 minutes in water at 37°C. Compliance with veterinary medicinal product GMP follows Regulation (EU) 2019/6 and, for US-oriented batches, 21 CFR Part 211. The terminal product is a scored 500 mg tablet in PVC/PVDC/aluminum blister packs, packaged with a desiccant sachet in a carton.

Capsule filling for companion-animal and calf digestive support requires tighter particle-size control than tablet granulation because size 00 hard gelatin capsules tolerate fill weights of 420–480 mg before weight variation exceeds acceptable limits. The formulation loads 180 mg API per capsule with lactose monohydrate q.s., 3% sodium starch glycolate, and 0.5% colloidal silicon dioxide. The powder blend is conditioned for 24 hours at 21–25°C and 35–45% RH before filling on a dosator capsule machine at 60,000 capsules/hour; fill weight variation is held at ±5% or better. Compliance follows veterinary cGMP under Regulation (EU) 2019/6, and release testing includes disintegration according to a capsule-adapted USP 701 method and microbial enumeration by ISO 4833-1:2013. The terminal dosage form is a hard gelatin capsule in 30-count HDPE bottles with a desiccant or 10-count aluminum/aluminum blisters, intended for oral administration to target veterinary species under prescription.

The main processing conflict in encapsulation is not powder flow but empty-shell brittleness when the filling suite exceeds 45% RH; hard gelatin shells stored without humidification crack on the tamping pins and produce split caps. Continuous production therefore uses shell conditioning chambers at 40–45% RH and observes a 30-minute maximum staging time before filling. Post-fill dedusting through a rotary brush cleaner reduces dust carryover on the filled shell surface, which is critical for veterinary products with potential cross-species handling at farms.

Fluidized-bed granulation of the powder begins with a binary blend of API and mannitol at an API weight fraction of 25%. The material is loaded into a top-spray fluid-bed dryer with a 2.5 m² perforated plate and sprayed with 5% w/w polyvinylpyrrolidone K30 solution at an inlet temperature of 55–65°C and product temperature of 32–38°C. Atomizing pressure is held at 2.0–2.5 bar and spray rate at 30–50 g/min/kg of bed mass to avoid overwetting hygroscopic extract particles. Granules are dried to residual moisture ≤5.0% w/w and sieved to a target D50 of 300–500 μm. Compliance for this dosage form includes granule uniformity of mass and extractable marker content per Chinese Veterinary Pharmacopoeia 2020, residual solvent testing per VICH GL18, and a total aerobic microbial count of ≤10⁴ CFU/g by ISO 4833-1:2013. The terminal product is an oral granule in 1 kg and 5 kg PET/aluminum/PE bags for feed top-dressing in ruminant and swine operations.

The dominant batch failure in fluidized-bed processing is attrition-generated fines below 75 μm, which segregate during in-feed top-dressing and create uneven intake. To reduce fines, the granule is sprayed with a final 0.5% povidone seal coat after drying and conveyed by mass-flow discharge rather than vacuum conveying. This step increases process time by 15–20 minutes but reduces the fines fraction from 8–12% to ≤3% on 200 kg production lots.

When Aqueous Herbal Extracts Are Converted into Sterile Injection Solutions, Filtration and Endotoxin Control Determine Feasibility

Injection-grade processing cannot use the raw API powder directly because botanical extract powders carry a particulate load and bacterial endotoxin burden that exceed parenteral limits. The downstream process starts with a water extraction at 80–90°C using a 6–8 fold solvent volume, followed by centrifugation at 12,000×g and ultrafiltration through a 10 kDa polyethersulfone membrane. The filtrate is adjusted to pH 5.5–6.5 and passed through a 0.45 μm prefilter and a 0.22 μm sterilizing-grade polyvinylidene fluoride filter before filling into type I glass vials and autoclaving at 121°C for 15 minutes. The addition ratio for injection development is not expressed as raw powder mass per millilitre; it is based on dried extract yield and marker compound assay, and published data for this specific configuration is limited. A development starting point of 0.5–1.0 g dried extract per 10 mL solution requires analytical method validation under VICH GL2 and residual solvent control under VICH GL18. Sterility testing follows Chinese Veterinary Pharmacopoeia 1101, bacterial endotoxin testing follows 1143, and particulate matter testing follows 0903. For food-producing animals, withdrawal-period determination follows VICH GL48. The terminal product is a 10 mL or 20 mL sterile solution in amber type I glass vials with rubber stoppers and aluminium caps.

Ultrafiltration membrane fouling is the principal production-scale bottleneck, with permeate flux declining by 30–50% after the first 2 hours of filtration unless a 0.45 μm clarification step and periodic backflushing are used. Endotoxin reduction requires steam-in-place cycles on all stainless steel vessels and a cleaning-in-place protocol using hot sodium hydroxide at 80°C; cold caustic washing alone does not remove extract-derived polysaccharide films. This dosage form is not a simple repackaging of the oral-grade powder, and formulators should treat each botanical lot as a new source material for extractable marker and impurity profiling.

Oral Drench Solutions at pH 4.0 Rely on Sodium Benzoate Rather Than Parabens

Liquid oral preparations are produced by dispersing the powder at 10–15% w/v in purified water with 0.1% sodium benzoate and citric acid to pH 4.0. Mixing in a high-shear homogenizer at 3000 rpm for 20 minutes reduces visible sediment and suspends hydrophobic extract fines; the batch is then passed through a 10 μm polypropylene filter and filled into 250 mL or 1 L HDPE bottles with induction seals. The API addition ratio is adjusted to the marker assay of the liquid, not to dry-weight only, because extraction residue can contribute 8–12% of the nominal dry mass. Compliance includes oral-liquid microbial limits per Chinese Veterinary Pharmacopoeia 1105/1106, pH and clarity specifications, and preservative efficacy testing by USP 51 or Ph. Eur. 5.1.3. The terminal product is an oral drench solution for calves and foals, administered by drench gun or as an in-feed liquid top-dress.

Sedimentation instability at pH above 4.5 is a known limitation; the protonated form of the extract acids keeps the suspended fraction dispersed, whereas higher pH values produce a dense sediment that cannot be redispersed by ordinary shaking. Production lines therefore verify homogenizer tip speed and shear time, not just pH, before filtration. If a paraben-preserved formulation is requested for a specific importing market, compatibility testing is mandatory because benzoate salts can partition into the extract phase and reduce free preservative concentration below the effective threshold.